Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

Post by prophetoffactzon Jun 28, 2024 10:39am
118 Views
Post# 36110665

11 business days before the AGM

11 business days before the AGMLast patient last visit for the diagnostic trial two weeks ago. How long for top-line results?

5X PGX scale-up almost completed two months ago and this scale-up was to provide partners with PGX materials. With the merger officially closed is it deal time? CZO had also designed an animal trial protocol for the immune booster as of November.

Data Safety Monitoring Board was to make its decision "shortly" one month ago concerning the next phase of the avenanthramide trial.

PGX-YBG/fibrosis was sent to a leading scientific journal recently as of two months ago and a short toxicology study was said all that was needed last October for a clinical trial go/no go decision.

 
<< Previous
Bullboard Posts
Next >>